Delray Medical Center cut the ribbon on its newest high-tech machine last week that targets brain areas to treat movement ...
Biogen’s proposed acquisition comes after two difficult years of regulatory and clinical challenges, during which shares of ...
A yearslong partner of neuroscience player Sage, Biogen already owns 10.2% of the Cambridge, Massachusetts-based biotech, ...
Sage Therapeutics Inc. (NASDAQ:SAGE) confirmed that Biogen Inc. (NASDAQ:BIIB) submitted an unsolicited, nonbinding proposal ...
Three blockbuster-potential assets in late-stage clinical trials and four pivotal readouts expected in 2025; anticipate four commercial assets by ...
Three blockbuster-potential assets in late-stage clinical trials and four pivotal readouts expected in 2025; anticipate four commercial assets by 2028 Study 1 of Essential3 program for ulixacaltamide ...
The $7.22-per-share deal for 89.8% of Sage is a 30% premium on the company's share price on Friday and is estimated by ...
What's stopping him? O'Brien suffers from a movement disorder called essential tremor – involuntary shaking that makes even the smallest tasks nearly impossible. "It's like I'm trying to relax ...
What's stopping him? O'Brien suffers from a movement disorder called essential tremor – involuntary shaking that makes even the smallest tasks nearly impossible. "It's like I'm trying to relax ...